|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/08/17 Opko Health, Inc. 10-Q 6/30/17 75:8.9M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 648K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
12: R1 Document and Entity Information HTML 40K
13: R2 Condensed Consolidated Balance Sheets HTML 100K
14: R3 Condensed Consolidated Balance Sheets HTML 30K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 94K
16: R5 Condensed Consolidated Statements of Comprehensive HTML 41K
Income (Loss)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 124K
18: R7 Business and Organization HTML 28K
19: R8 Summary of Significant Accounting Policies HTML 77K
20: R9 Earnings (Loss) Per Share HTML 78K
21: R10 Composition of Certain Financial Statement HTML 122K
Captions
22: R11 Acquisitions, Investments and Licenses HTML 60K
23: R12 Debt HTML 125K
24: R13 Accumulated Other Comprehensive Income (Loss) HTML 38K
25: R14 Fair Value Measurements HTML 140K
26: R15 Derivative Contracts HTML 54K
27: R16 Related Party Transactions HTML 35K
28: R17 Commitments and Contingencies HTML 32K
29: R18 Strategic Alliances HTML 50K
30: R19 Segments HTML 153K
31: R20 Subsequent Events HTML 23K
32: R21 Summary of Significant Accounting Policies HTML 136K
(Policies)
33: R22 Earnings (Loss) Per Share (Tables) HTML 72K
34: R23 Composition of Certain Financial Statement HTML 123K
Captions (Tables)
35: R24 Acquisitions, Investments and Licenses (Tables) HTML 48K
36: R25 Debt (Tables) HTML 110K
37: R26 Accumulated Other Comprehensive Income (Loss) HTML 38K
(Tables)
38: R27 Fair Value Measurements (Tables) HTML 141K
39: R28 Derivative Contracts (Tables) HTML 55K
40: R29 Segments (Tables) HTML 151K
41: R30 Business and Organization (Details) HTML 34K
42: R31 Summary of Significant Accounting Policies HTML 130K
(Details)
43: R32 Earnings (Loss) Per Share - Schedule of Earnings HTML 59K
Per Share (Details)
44: R33 Earnings (Loss) Per Share - Narrative (Details) HTML 33K
45: R34 Composition of Certain Financial Statement HTML 138K
Captions (Details)
46: R35 Composition of Certain Financial Statement HTML 57K
Captions - Changes in Goodwill (Details)
47: R36 Acquisitions, Investments and Licenses - HTML 32K
Acquisition Narrative (Details)
48: R37 Acquisitions, Investments and Licenses - HTML 44K
Transition Therapeutics Purchase Price Allocation
(Details)
49: R38 Acquisitions, Investments and Licenses - Summary HTML 37K
of Investments (Details)
50: R39 Acquisitions, Investments and Licenses - Equity HTML 57K
and Cost Method Investments Narrative (Details)
51: R40 Acquisitions, Investments and Licenses - Available HTML 51K
for Sale Investments, Sale of Investments and
Warrants and Options Narrative (Details)
52: R41 Acquisitions, Investments and Licenses - Variable HTML 33K
Interest Entities Narrative (Details)
53: R42 Acquisitions, Investments and Licenses - Other HTML 40K
Narrative (Details)
54: R43 Debt - Narrative (Details) HTML 143K
55: R44 Debt - Notes (Details) HTML 51K
56: R45 Debt - Inputs Used In Lattice Model (Details) HTML 40K
57: R46 Debt - Fair Value Of Embedded Derivatives HTML 28K
(Details)
58: R47 Debt - Lines Of Credit (Details) HTML 60K
59: R48 Debt - Mortgage Notes And Other Debt (Details) HTML 31K
60: R49 Accumulated Other Comprehensive Income (Loss) HTML 43K
(Details)
61: R50 Fair Value Measurements - Summary Of Investments HTML 35K
(Details)
62: R51 Fair Value Measurements - Assets And Liabilities HTML 54K
Measured At Fair Value (Details)
63: R52 Fair Value Measurements - Notes (Details) HTML 29K
64: R53 Fair Value Measurements - Level 3 Reconciliation HTML 36K
(Details)
65: R54 Fair Value Measurements - Narrative (Details) HTML 33K
66: R55 Derivative Contracts - Balance Sheet Component HTML 39K
(Details)
67: R56 Derivative Contracts - Derivative Gains (Losses) HTML 32K
(Details)
68: R57 Related Party Transactions (Details) HTML 164K
69: R58 Commitments and Contingencies (Details) HTML 36K
70: R59 Strategic Alliances (Details) HTML 104K
71: R60 Segments - Narrative (Details) HTML 41K
72: R61 Segments - Operations and Assets Information HTML 78K
(Details)
74: XML IDEA XML File -- Filing Summary XML 132K
73: EXCEL IDEA Workbook of Financial Reports XLSX 106K
6: EX-101.INS XBRL Instance -- opk-20170630 XML 2.77M
8: EX-101.CAL XBRL Calculations -- opk-20170630_cal XML 251K
9: EX-101.DEF XBRL Definitions -- opk-20170630_def XML 971K
10: EX-101.LAB XBRL Labels -- opk-20170630_lab XML 1.93M
11: EX-101.PRE XBRL Presentations -- opk-20170630_pre XML 1.20M
7: EX-101.SCH XBRL Schema -- opk-20170630 XSD 180K
75: ZIP XBRL Zipped Folder -- 0000944809-17-000008-xbrl Zip 290K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
August 8, 2017 | |
Chief Executive Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/8/17 | 4, 8-K | ||
| For Period end: | 6/30/17 | 4 | ||
| List all Filings | ||||